

Appl. No. 09/927,006  
Response. Dated December 22, 2004  
Reply to Office Action of September 22, 2004

RECEIVED  
CENTRAL FAX CENTER  
DEC 22 2004

PATENT APPLICATION


*IN THE UNITED STATES PATENT AND TRADEMARK OFFICE*

Group  
Art Unit: 1654  
  
Attorney  
Docket No.: 130654-001  
  
Applicant: Dexian Dou et al.  
  
Invention: ANTI-ANGIOGENIC PEPTIDES FOR  
CANCER TREATMENT  
  
Serial No: 09/927,006  
  
Filed: August 9, 2003  
  
Examiner: B. Dell Chism

Certificate Under 37 CFR 1.8(b)

I hereby certify that this correspondence is being  
transmitted to the United States Patent and Trademark  
Office via facsimile transmission on the date indicated  
below.

on December 22, 2004

  
Michael S. Gzybowski

AMENDMENT

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Official Communication mailed May 27, 2004 in connection with the  
above-identified application, please amend the application as follows.

Amendments to the Claims are reflected in the listing of the claims which begins on page 2  
of this paper.

Remarks/Arguments begin on page 7 of this paper.

**CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)**Applicant(s): **Dexian Dou et al.**

Docket No.

**130654-001**

Application No.

**09/927,006**

Filing Date

**August 9, 2001**


Examiner


**Billy Chism**

Group Art Unit

**1654**

Invention:

**ANTI-ANGIOGENIC PEPTIDES FOR CANCER TREATMENT****RECEIVED  
CENTRAL FAX CENTER****DEC 22 2004**I hereby certify that this Amendment and Amendment Transmittal*(Identify type of correspondence)*is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306)on December 22, 2004*(Date)***Michael S. Gzybowski***(Typed or Printed Name of Person Signing Certificate)*  
*(Signature)***Note: Each paper must have its own certificate of mailing.**

AMENDMENT TRANSMITTAL LETTER (Small Entity)				Docket No. 130654-001	
Applicant(s): <b>Dexian DOU et al.</b>					
Application No. <b>09/927,006</b>	Filing Date <b>August 9, 2001</b>	Examiner <b>Billy Chism</b>	Customer No. <b>35684</b>	Group Art Unit <b>1654</b>	Confirmation No. <b>4184</b>
Invention: <b>ANTI-ANGIOGENIC PEPTIDES FOR CANCER TREATMENT</b>					
<b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.				<b>RECEIVED CENTRAL FAX CENTER DEC 22 2004</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	8 -	20 =	0 x	\$9.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0 x	\$44.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____					
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>12-2136</b>					
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.					
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 Signature			Dated: <b>December 22, 2004</b>		
Filed via facsimile transmission					
<div style="font-size: small;">I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____</div> <div style="text-align: center;">(Date)</div> <div style="text-align: center;">_____ Signature of Person Mailing Correspondence</div> <div style="text-align: center;">_____ Typed or Printed Name of Person Mailing Correspondence</div>					
CC:					